市場調査レポート
商品コード
1452619

アジア太平洋地域の細胞・遺伝子治療製造サービス市場の2030年までの予測-地域別分析-タイプ別、適応症別、用途別、エンドユーザー別

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 - Regional Analysis - by Type, Indication (Cancer, Orthopedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), and End User

出版日: | 発行: The Insight Partners | ページ情報: 英文 112 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.54円
アジア太平洋地域の細胞・遺伝子治療製造サービス市場の2030年までの予測-地域別分析-タイプ別、適応症別、用途別、エンドユーザー別
出版日: 2024年01月15日
発行: The Insight Partners
ページ情報: 英文 112 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アジア太平洋の細胞・遺伝子治療製造サービス市場は、2022年の10億742万米ドルから2030年には36億1,318万米ドルに成長すると予測されています。2022年から2030年までのCAGRは17.3%と推定されます。

細胞・遺伝子治療製造サービスの自動化がアジア太平洋の細胞・遺伝子治療製造サービス市場を牽引

細胞・遺伝子治療製造に自動化を取り入れることは、汚染リスクの低減、一貫性の向上、製造コストの削減につながります。LonzaのCocoonやMiltenyiのCliniMACS Prodigyシステムは、自動化を可能にする市場で入手可能な装置の一部です。これらの製品は、単一システム内でCAR-Tプロセスのほとんどの連続的な単位操作を自動化できるように設計されています。細胞・遺伝子治療に対する需要の高まりにより、細胞・遺伝子治療製品の生産は、世界的に少量生産から大量生産へとシフトしています。研究活動の活発化に加え、細胞・遺伝子治療が学術的・臨床的環境から大量生産・商業化へと進化したことで、商業生産における自動化の需要が高まっています。2020年7月、Thermo Fisher Scientific Inc.とLyell Immunopharmaは、がん患者に対する効果的な細胞療法をデザインするプロセスの開発と製造のために提携しました。この提携の下、両社はT細胞の能力を向上させることを目指し、試薬、消耗品、機器とともに、cGMP(current good manufacturing practice)に準拠した統合プラットフォーム(システムとソフトウェア)の開発をサポートします。このように、自動化はアジア太平洋の細胞・遺伝子治療製造サービス市場における新たな動向として浮上しています。

アジア太平洋の細胞・遺伝子治療製造サービス市場概要

アジア太平洋は、中国、日本、インド、オーストラリア、韓国、その他のアジア太平洋で構成されています。アジア太平洋は、細胞・遺伝子治療セグメントの主要地域のひとつであり、これらの治療法の研究開発に投資している国がいくつかあります。細胞・遺伝子治療に関しては、日本はアジア太平洋のリーダーの1つです。2014年、日本は黄斑変性症の治療薬である細胞治療製品を承認した最初の国となりました。それ以降も、白血病やリンパ腫に対するCAR-Tなど、いくつかの細胞・遺伝子治療が国内で承認されています。

中国は2003年に遺伝子治療を承認した最初の国であり、それ以来、細胞治療と遺伝子治療の開発は世界中で急速に進み、その治療の可能性は急上昇しています。中国政府は、細胞・遺伝子治療の規範的発展を促進するため、いくつかの規制改革を行ってきました。2021年にネイチャー誌に発表された研究によると、中国は世界の細胞治療試験の50%以上を実施しています。現在、中国では血液学、腫瘍学、固形がんを中心に400近くのCAR-T試験が進行中です。中国では、2021年にFosun KiteのYescartaとJW TherapeuticsのRelma-celが国家医薬品監督管理局(NMPA)から承認され、細胞治療は新たな時代を迎えようとしています。コストの低下と患者数の増加により、複数の多国籍企業がこれらの要因を活用するためにこの地域に進出しています。

アジア太平洋の細胞・遺伝子治療製造サービス市場の収益と2030年までの予測(金額)

アジア太平洋の細胞・遺伝子治療製造サービス市場のセグメンテーション

アジア太平洋の細胞・遺伝子治療製造サービス市場は、タイプ、適応症、用途、エンドユーザー、国に区分されます。

タイプ別では、アジア太平洋の細胞・遺伝子治療製造サービス市場は細胞治療と遺伝子治療に二分されます。2022年、アジア太平洋の細胞・遺伝子治療製造サービス市場では、細胞治療セグメントがより大きなシェアを記録しました。細胞療法セグメントはさらに自己由来と同種異系に区分されます。遺伝子治療セグメントはさらに、ウイルスベクターと非ウイルスベクターに区分されます。

適応症に基づき、アジア太平洋の細胞・遺伝子治療製造サービス市場は、がん、整形外科、その他に区分されます。2022年には、がんセグメントがアジア太平洋の細胞・遺伝子治療製造サービス市場で最大のシェアを記録しました。

用途別では、アジア太平洋の細胞・遺伝子治療製造サービス市場は臨床製造と商業製造に区分されます。2022年には、商業用製造セグメントがアジア太平洋の細胞・遺伝子治療製造サービス市場で最大のシェアを記録しました。

エンドユーザーに基づき、アジア太平洋の細胞・遺伝子治療製造サービス市場は製薬・バイオテクノロジー企業と契約研究機関(CRO)に二分されます。2022年、アジア太平洋の細胞・遺伝子治療製造サービス市場では、製薬・バイオテクノロジー企業セグメントがより大きなシェアを記録しました。

国別に見ると、アジア太平洋の細胞・遺伝子治療製造サービス市場は、中国、日本、インド、オーストラリア、韓国、その他のアジア太平洋に区分されます。2022年、中国はアジア太平洋の細胞・遺伝子治療製造サービス市場で最大のシェアを記録しました。

Catalent Inc、Charles River Laboratories International Inc、FUJIFILM Holdings Corp、Lonza Group AG、Merck KgaA、Nikon Corp、Takara Bio Inc、Thermo Fisher Scientific Inc、WuXi AppTec Co Ltdは、アジア太平洋の細胞・遺伝子治療製造サービス市場で事業を展開している大手企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 アジア太平洋の細胞・遺伝子治療製造サービス市場-主要産業力学

  • 主要市場の促進要因
    • 細胞・遺伝子治療の承認件数の増加
    • 細胞・遺伝子治療製造アウトソーシングの人気上昇
  • 市場抑制要因
    • 細胞・遺伝子治療製造の高コスト
  • 市場機会
    • 企業による戦略的取り組み
  • 今後の動向
    • 細胞・遺伝子治療製造サービスの自動化
  • 影響分析

第5章 細胞・遺伝子治療製造サービス市場:アジア太平洋市場分析

  • アジア太平洋の細胞・遺伝子治療製造サービス市場売上高、2022~2030年

第6章 アジア太平洋の細胞・遺伝子治療製造サービス市場:2030年までの収益と予測:タイプ別

  • イントロダクション
  • アジア太平洋の細胞・遺伝子治療製造サービス市場2022年・2030年売上高シェア(%):タイプ別
  • 細胞療法
  • 遺伝子治療

第7章 アジア太平洋の細胞・遺伝子治療製造サービス市場の2030年までの分析と予測:適応症別

  • イントロダクション
  • アジア太平洋の細胞・遺伝子治療製造サービス市場:2022年・2030年(%):適応症別
  • がん
  • 整形外科
  • その他

第8章 アジア太平洋の細胞・遺伝子治療製造サービス市場:収益と2030年までの予測:用途別

  • イントロダクション
  • アジア太平洋の細胞・遺伝子治療製造サービス市場2022年・2030年売上高シェア(%):用途別
  • 臨床製造
  • 商業用製造

第9章 アジア太平洋の細胞・遺伝子治療製造サービス市場:2030年までの収益と予測:エンドユーザー別

  • イントロダクション
  • アジア太平洋細胞・遺伝子治療製造サービス市場売上高シェア 2022年・2030年(%):エンドユーザー別
  • 製薬企業とバイオテクノロジー企業
  • CRO(医薬品開発業務受託機関)

第10章 アジア太平洋の細胞・遺伝子治療製造サービス市場:2030年までの収益と予測:国別分析

    • アジア太平洋
      • 中国
      • 日本
      • インド
      • オーストラリア
      • 韓国
      • その他のアジア太平洋

第11章 アジア太平洋の細胞・遺伝子治療製造サービス市場:業界情勢

  • イントロダクション
  • アジア太平洋の細胞・遺伝子治療製造サービス市場における成長戦略
  • 有機的成長戦略
  • 無機的成長戦略

第12章 企業プロファイル

  • Thermo Fisher Scientific Inc
  • Merck KGaA
  • Charles River Laboratories International Inc
  • Lonza Group AG
  • WuXi AppTec Co Ltd
  • Catalent Inc
  • Takara Bio Inc
  • Nikon Corp
  • FUJIFILM Holdings Corp
図表

List Of Tables

  • Table 1. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Segmentation
  • Table 2. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
  • Table 3. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
  • Table 4. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
  • Table 5. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
  • Table 6. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
  • Table 7. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • Table 8. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
  • Table 9. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
  • Table 10. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
  • Table 11. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million
  • Table 12. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
  • Table 13. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • Table 14. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
  • Table 15. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
  • Table 16. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
  • Table 17. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
  • Table 18. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
  • Table 19. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • Table 20. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
  • Table 21. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
  • Table 22. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
  • Table 23. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
  • Table 24. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
  • Table 25. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • Table 26. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
  • Table 27. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
  • Table 28. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
  • Table 29. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
  • Table 30. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
  • Table 31. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • Table 32. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
  • Table 33. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
  • Table 34. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
  • Table 35. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
  • Table 36. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
  • Table 37. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  • Table 38. Recent Organic Growth Strategies in Asia Pacific Cell and Gene Therapy Manufacturing Services Market
  • Table 39. Recent Inorganic Growth Strategies in the Asia Pacific Cell and Gene Therapy Manufacturing Services Market

List Of Figures

  • Figure 1. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Segmentation, By Country
  • Figure 2. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Key Industry Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue (US$ Mn), 2022 - 2030
  • Figure 5. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
  • Figure 6. Cell Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Autologous: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Allogenic: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Gene Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Non-Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
  • Figure 13. Cancer: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Orthopedics: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Others: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
  • Figure 17. Clinical Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Commercial Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
  • Figure 20. Pharmaceutical & Biotechnology Companies: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Contract Research Organizations (CROs): Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 22. Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Key Region - Revenue (2022) (US$ Million)
  • Figure 23. Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
  • Figure 24. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 26. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 27. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 28. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 29. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 30. Growth Strategies in Asia Pacific Cell and Gene Therapy Manufacturing Services Market
目次
Product Code: BMIRE00029300

The Asia Pacific cell and gene therapy manufacturing services market is expected to grow from US$ 1,007.42 million in 2022 to US$ 3,613.18 million by 2030. It is estimated to grow at a CAGR of 17.3% from 2022 to 2030.

Automation of Cell and Gene Therapy Manufacturing Services Drives Asia Pacific Cell and Gene Therapy Manufacturing Services Market

Incorporating automation in cell and gene therapy manufacturing would lead to a reduced risk of contamination, improved consistency, and decreased cost of production. Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are a few of the devices available in the market to enable automation. These products have been designed to enable the automation of most sequential unit operations for a CAR-T process within a single system. The rising demand for cell and gene therapies has shifted the production of cell and gene therapy products from a small-volume process to a large-volume process worldwide. In addition to the increasing research activities, the evolution of cell and gene therapy from an academic and clinical setting to mass production and commercialization has propelled the demand for automation in commercial manufacturing. In July 2020, Thermo Fisher Scientific Inc. and Lyell Immunopharma partnered to develop and manufacture processes to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve the capability of T-cells and support the development of an integrated current good manufacturing practice (cGMP) compliant platform (system and software), along with reagents, consumables, and instruments. Thus, automation is emerging as a new trend in the Asia Pacific cell and gene therapy manufacturing services market.

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Overview

Asia Pacific region comprises of China, Japan, India, Australia, South Korea, and Rest of Asia Pacific countries. The Asia Pacific region is one of the leading regions in the field of cell and gene therapy, with several countries which are involved in the investing in research and development of these therapies. Japan is one of the leaders in the Asia Pacific region when it comes to cell and gene therapies. In 2014, Japan was the first country to approve a cell therapy product, a treatment for macular degeneration. Several other cell and gene therapies have been approved in the country since then, including the CAR-T for leukemia and lymphoma.

China is the first country to approve a gene therapy in 2003, since then cell and gene therapy development has advanced rapidly worldwide, and their therapeutic potential has soared. China's government has conducted several regulatory reforms to promote normative development of cell and gene therapies. According to a study published in Nature in 2021, China is home to more than 50% of all cell therapy trials across the world. Currently, China has nearly 400 ongoing CAR-T trials centered on hematology and oncology and solid tumors. Cell therapy in China is entering a new era with the approval of Fosun Kite's Yescarta and JW Therapeutics' Relma-cel in 2021 from the National Medical Products Administration (NMPA). Due to lower costs and larger patient populations, several multinational companies have moved to the region to take advantage of these factors.

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Segmentation

The Asia Pacific cell and gene therapy manufacturing services market is segmented into type, indication, application, end user, and country.

Based on type, the Asia Pacific cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. In 2022, the cell therapy segment registered a larger share in the Asia Pacific cell and gene therapy manufacturing services market. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.

Based on indication, the Asia Pacific cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. In 2022, the cancer segment registered the largest share in the Asia Pacific cell and gene therapy manufacturing services market.

Based on application, the Asia Pacific cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. In 2022, the commercial manufacturing segment registered the largest share in the Asia Pacific cell and gene therapy manufacturing services market.

Based on end user, the Asia Pacific cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). In 2022, the pharmaceutical and biotechnology companies segment registered a larger share in the Asia Pacific cell and gene therapy manufacturing services market.

Based on country, the Asia Pacific cell and gene therapy manufacturing services market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2022, China registered the largest share in the Asia Pacific cell and gene therapy manufacturing services market.

Catalent Inc, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Lonza Group AG, Merck KgaA, Nikon Corp, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd are some of the leading companies operating in the Asia Pacific cell and gene therapy manufacturing services market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Key Industry Dynamics

  • 4.1 Key Market Drivers:
    • 4.1.1 Increase in Number of Approval of Cell and Gene Therapies
    • 4.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
  • 4.2 Market Restraints
    • 4.2.1 High Cost of Cell and Gene Therapy Manufacturing
  • 4.3 Market Opportunities
    • 4.3.1 Strategic Initiatives by Companies
  • 4.4 Future Trends
    • 4.4.1 Automation of Cell and Gene Therapy Manufacturing Services
  • 4.5 Impact Analysis:

5. Cell and Gene Therapy Manufacturing Services Market - Asia Pacific Market Analysis

  • 5.1 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue (US$ Mn), 2022 - 2030

6. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Type

  • 6.1 Overview
  • 6.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
  • 6.3 Cell Therapy
    • 6.3.1 Overview
    • 6.3.2 Cell Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.3.2.1 Autologous
        • 6.3.2.1.1 Overview
        • 6.3.2.1.2 Autologous: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.3.2.2 Allogenic
        • 6.3.2.2.1 Overview
        • 6.3.2.2.2 Allogenic: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Gene Therapy
    • 6.4.1 Overview
    • 6.4.2 Gene Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.4.2.1 Viral Vector
        • 6.4.2.1.1 Overview
        • 6.4.2.1.2 Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.4.2.2 Non-Viral Vector
        • 6.4.2.2.1 Overview
        • 6.4.2.2.2 Non-Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Analysis and Forecasts to 2030 - by Indication

  • 7.1 Overview
  • 7.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
  • 7.3 Cancer
    • 7.3.1 Overview
    • 7.3.2 Cancer: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Orthopedics
    • 7.4.1 Overview
    • 7.4.2 Orthopedics: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Others
    • 7.5.1 Overview
    • 7.5.2 Others: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Application

  • 8.1 Overview
  • 8.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
  • 8.4 Clinical Manufacturing
    • 8.4.1 Overview
    • 8.4.2 Clinical Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Commercial Manufacturing
    • 8.5.1 Overview
    • 8.5.2 Commercial Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by End User

  • 9.1 Overview
  • 9.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
  • 9.4 Pharmaceutical and Biotechnology Companies
    • 9.4.1 Overview
    • 9.4.2 Pharmaceutical & Biotechnology Companies: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Contract Research Organizations (CROs)
    • 9.5.1 Overview
    • 9.5.2 Contract Research Organizations (CROs): Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - Country Analysis

  • 10.1 Overview
    • 10.1.1 Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
      • 10.1.1.1 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.1.1 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 10.1.1.1.1.1 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 10.1.1.1.1.2 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 10.1.1.1.2 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 10.1.1.1.3 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.1.4 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.2 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 10.1.1.2.1.1 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 10.1.1.2.1.2 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 10.1.1.2.2 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 10.1.1.2.3 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.2.4 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.3 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 10.1.1.3.1.1 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 10.1.1.3.1.2 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 10.1.1.3.2 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 10.1.1.3.3 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.3.4 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.4 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 10.1.1.4.1.1 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 10.1.1.4.1.2 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 10.1.1.4.2 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 10.1.1.4.3 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.4.4 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.5 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.1 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 10.1.1.5.1.1 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 10.1.1.5.1.2 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 10.1.1.5.2 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 10.1.1.5.3 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.5.4 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.6 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.1 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
        • 10.1.1.6.1.1 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
        • 10.1.1.6.1.2 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
        • 10.1.1.6.2 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
        • 10.1.1.6.3 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.6.4 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)

11. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Asia Pacific Cell and Gene Therapy Manufacturing Services Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Thermo Fisher Scientific Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Merck KGaA
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Charles River Laboratories International Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Lonza Group AG
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 WuXi AppTec Co Ltd?
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Catalent Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Takara Bio Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Nikon Corp
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 FUJIFILM Holdings Corp
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments